Jefferies Starts Sagent Pharmaceuticals (SGNT) at Buy
Get Alerts SGNT Hot Sheet
Price: $21.76 --0%
Rating Summary:
1 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 5
Rating Summary:
1 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 5
Join SI Premium – FREE
Jefferies initiates coverage on Sagent Pharmaceuticals (NASDAQ: SGNT) with a Buy and $31 price target.
The firm states, "Sagent is one of a few standalone generic injectables companies, and given high barriers to entry and limited competition, has compelling scarcity value. With a low-cost business model that should support significant future margin expansion, one of the industry's largest pipelines, and a management team with a track record of success, we initiate coverage at a Buy and $31 PT."
For more ratings news on Sagent Pharmaceuticals click here and for the rating history of Sagent Pharmaceuticals click here.
Shares of Sagent Pharmaceuticals closed at $25.43 yesterday.
The firm states, "Sagent is one of a few standalone generic injectables companies, and given high barriers to entry and limited competition, has compelling scarcity value. With a low-cost business model that should support significant future margin expansion, one of the industry's largest pipelines, and a management team with a track record of success, we initiate coverage at a Buy and $31 PT."
For more ratings news on Sagent Pharmaceuticals click here and for the rating history of Sagent Pharmaceuticals click here.
Shares of Sagent Pharmaceuticals closed at $25.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Berenberg Starts Deutsche Bank ADRs (DB) at Hold, Maintains Hold on German Shares
- DAM Capital Starts Apollo Tyres (APTY:IN) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!